The study found that exercise time improved by 28.4 seconds in PCI-treated patients, but not significantly in sham-PCI treated patients. SCAI questions the reliability of the findings due to the small number of patients and subjective endpoint used.
Researchers found that a simple index based on systolic blood pressure and left-ventricular end-diastolic blood pressure ratio can predict in-hospital mortality for patients with STEMI. The study included 219 patients and showed that the SBP/LVEDP ratio was more predictive than other indices.
A meta-analysis of randomized-clinical trials found that full-dose bivalirudin infusion post-PCI for four hours is associated with improved net adverse clinical events and all-cause mortality. Bivalirudin exhibits a lower risk of bleeding compared to unfractionated heparin, but also increases the risk of acute stent thrombosis.
A meta-analysis of 19,760 patients found S-DAPT associated with higher rates of myocardial infarction but lower TIMI major bleeding compared to L-DAPT. The optimal DAPT duration remains unclear due to varying patient risks and agent choices.
A new analysis reveals that early treatment for Non-ST-Elevation Myocardial Infarction (NSTEMI) patients leads to a significant reduction in mortality. The study found an 87% lower mortality rate and a 38% lower mortality rate for high-risk patients when treated within 24 hours of symptom onset.
The Society for Cardiovascular Angiography and Interventions (SCAI) has recognized outstanding SCAI members for their contributions to the field of interventional cardiology, education, and patient care. This year's award recipients include George Vetrovec, MD, MSCAI, and nine Master Interventionalists, who have demonstrated a commitme...
The PRECISION trial demonstrated clinical and technical success for patients undergoing robotic percutaneous coronary intervention (PCI) using radial or femoral access. Technical success rates were higher for transradial access procedures, while clinical success rates showed similar outcomes between both approaches.
A subgroup analysis of the BRAVO-3 trial found that patients with balloon expandable valves had a different baseline profile than those treated with non-balloon expandable valves. This suggests that differences in patient characteristics, not valve type, drive TAVR outcomes.
A new study found that women and minorities undergoing PCI are at higher risk of recurrent cardiac events due to their race, gender, and socioeconomic status. The PLATINUM Diversity trial enrolled a large sample of diverse patients and showed significant differences in adjusted outcomes between groups.
Researchers found that injecting an anti-inflammatory steroid directly into the tissue surrounding a leg artery reduced inflammatory biomarkers and prevented repeat blockages. The treatment showed promise for improving treatment outcomes for patients with peripheral artery disease.
A meta-analysis of three trials found that CD34+ stem cells improved exercise time by 80.5 seconds and reduced mortality by 24 months in patients with refractory angina. This therapy has been shown to be safe and effective for treating patients with limited options.
Patients with new-onset atrial fibrillation post-TAVR have a nearly five-fold greater risk of early stroke compared to those without AF. The BRAVO-3 trial found that patients with existing or new AF had higher rates of pre-existing comorbidities and were more likely to receive oral anticoagulants.
The Society for Cardiovascular Angiography and Interventions has selected 12 emerging interventional cardiologists for the Emerging Leader Mentorship (ELM) program. The two-year mentorship program aims to refine their skills as leaders in medicine, ambassadors for their specialty, and advocates for their patients.
A new position paper provides consensus recommendations for ionizing radiation dose optimization in pediatric patients with congenital and acquired heart disease. The guidelines focus on strategies to minimize radiation exposure while maintaining effective imaging procedures.
The new expert consensus statement provides recommendations for patient monitoring and sedation administration during pediatric cardiac catheterization procedures. Key findings highlight the need for standardized practices to minimize anesthesia-related morbidity and mortality in patients with congenital heart disease.
A retrospective study found that young women undergoing PCI for acute coronary syndrome experience higher rates of adverse cardiovascular events and bleeding risks compared to men. The study highlights the importance of objectively assessing all risk factors when prescribing antiplatelet therapy.
A large observational study demonstrated that moderate sedation use is linked to better patient outcomes for TAVR patients. Moderate sedation was found to reduce 30-day mortality rates by 23% and shorten hospital stays by approximately 1 day compared to general anesthesia.
A study of TAVR patients using different anticoagulation medications found comparable survival and vascular complication rates between men and women. However, a trend was observed that women given bivalirudin experienced less mortality, warranting further investigation.
A study of over 23,000 patients found that women had a lower risk of comorbidities and experienced fewer vascular complications in-hospital after TAVR. Despite this, women's one-year survival rate was still higher than men's.
Patients treated with processed autologous adipose-derived regenerative cells (ADRCs) demonstrated symptomatic improvement and reduced heart failure hospitalizations. The ATHENA trial results showed a trend towards lower rates of angina, despite no improvement in left ventricle ejection fraction (LVEF) or ventricular volumes.
A study using stem cell therapy to treat refractory angina (RA) demonstrated promising results, including improved exercise time, reduced angina, and lower mortality rates. The treatment showed potential for difficult-to-treat RA patient population, offering a new approach for patients with limited treatment options.
A new device called AVERT significantly reduced the volume of radiographic dye used in patients at risk of developing acute kidney injury (AKI) during coronary angiography and PCI, but did not reduce contrast-induced AKI. The study found a 15.5% relative reduction in CMV for all patients and a 22.8% reduction for PCI patients.
A new study has demonstrated the safety and feasibility of robotically assisted percutaneous coronary intervention (PCI) in patients with complex coronary lesions. Similar clinical outcomes were achieved compared to manual PCI procedures, with no increase in resource utilization or patient radiation exposure reported.
A national hospital system reduced bleeding events by 40% for PCI patients using a risk-directed approach and the National Cardiovascular Data Registry's bleeding risk calculator. This resulted in significant cost savings, with estimated reductions of approximately $1 million.
The SCAI 2016 Mullins Lecture by Andrew Redington discusses breakthrough advances in cath lab treatments for the failing subpulmonary right ventricle. The lecture highlights the tremendous opportunity for interventional cardiologists to develop new treatment options for their patients.
The SCAI 2016 Hildner Lecture explores how surgery and cardiology merged to form the catheterization laboratory, revolutionizing cardiac therapy. Dr. Forrester discusses the key individuals who drove this evolution, including Dwight Harken and F. Mason Sones Jr.
The Society for Cardiovascular Angiography and Interventions (SCAI) has released updated guidelines for cardiac catheterization laboratory (CCL) best practices. The new guidelines aim to improve the quality of care, enhance patient satisfaction, and promote consistency in cath lab operations.
The Society for Cardiovascular Angiography and Interventions has released a consensus statement providing guidance for treating patients with concomitant cardiovascular disease and cancer. The document aims to increase the competency of cardiovascular professionals in caring for cancer patients, who are expected to increase to 20 milli...
A study found African-Americans at greater risk after PCI with significantly worse outcomes, despite researchers' efforts to provide optimal care. Possible explanations include delayed treatment, advanced coronary disease, and poor medication adherence.
A novel PFO closure system has been found to be safe and effective at 90 days, with 89% of patients achieving complete or clinical closure. The FlatStent EF system is designed to reduce the risk of blood clots and other complications associated with current PFO closure systems.
The CARILLON Mitral Contour System safely treats leaky mitral valves even in patients with moderate-to-severe heart failure. After treatment, patients experienced less shortness of breath and reported a better quality of life.
Two studies show that women who undergo angioplasty for heart attacks are often older, in poorer condition, and have delayed recognition of symptoms. As a result, they face twice the likelihood of procedural failure and an increased risk of death compared to men.
A new study by the Society for Cardiovascular Angiography and Interventions found that proton pump inhibitors, commonly used to treat heartburn, can compromise the anti-clotting action of clopidogrel. This can lead to a higher risk of hospitalization for heart attack, stroke, and other serious cardiovascular illnesses.
The SAPPHIRE trial found that carotid stenting was comparably effective to surgery in preventing stroke, heart attack, and death in high-risk patients. Patients undergoing stenting had similar rates of revascularization procedures as those who underwent surgery.
A large randomized study found that angioplasty and stenting offer no benefit over medical therapy for patients with renal artery stenosis. After one year of follow-up, there were no differences in kidney function, blood pressure control, or major cardiovascular illness rates.
A new study found that an iso-osmolar X-ray dye did not reduce the risk of kidney damage during percutaneous coronary intervention (PCI) in patients with chronic renal failure. The study compared two types of contrast medium and found no significant difference in rates of kidney injury or need for dialysis.
A small study of MitraClip procedure shows significant reduction in mitral regurgitation and improvement in heart function, including reduced left ventricular enlargement. Patients experienced mild to modest mitral regurgitation after treatment, and continued to enjoy improved symptoms and daily function.
The study found that clopidogrel reloading significantly improves clinical outcomes without increasing the risk of bleeding, particularly in patients with acute coronary syndromes. Clopidogrel reloading reduces the combined risk of death, heart attack or repeat coronary procedure by nearly two-thirds in these patients.
The ExoSeal vascular closure device significantly reduced bleeding time, enabling patients to get up and walk around far sooner than with manual compression. The study found no access site complications at 30 days, a promising result for the safety and effectiveness of the device.
A study found that diabetic patients who continued long-term clopidogrel therapy had lower rates of heart attack and death compared to those who discontinued the medication, regardless of stent type. Long-term clopidogrel therapy was particularly beneficial in reducing mortality risk with bare metal stents.
A study by Society for Cardiovascular Angiography and Interventions (SCAI) uses wireless technology to transmit ECGs from paramedics' smartphones to cardiologists, allowing for faster treatment of heart attacks. The system has cut the door-to-balloon time in half, improving patient care.
Pretreatment with high-dose clopidogrel (600 mg or more) reduces the risk of cardiac death or nonfatal heart attack by 50% during hospitalization and within 30 days after PCI. The study found no increase in major or minor bleeding, regardless of dose.
Renowned experts Roxanna Mehran and Michael J. Mack debate the role of stenting versus bypass surgery in treating left main coronary artery disease. The Synergy Between PCI With Taxus and Cardiac Surgery trial is expected to provide critical data on the effectiveness of drug-eluting stents compared to bypass surgery.
Experts disagree on the criticality of a 90-minute door-to-balloon time in heart attack treatment. Dr. Eric R. Bates believes that timely balloon inflation is crucial for better outcomes, while Dr. Timothy D. Henry argues that an arbitrary deadline may be counterproductive in some cases.
A minimally invasive stenting procedure has shown promising results in treating chronic mesenteric ischemia, a condition similar to intestinal angina. The technique was successful in 96% of patients, with over 90% experiencing relief from abdominal pain and weight gain.
A novel catheter technique successfully patched ventricular septal defects (VSDs) in nearly all patients, restoring normal blood circulation and relieving fluid backup in the lungs. After recovery, patients regained enough strength to safely undergo surgical repair or return to active lives.
Catheter-based aortic valve replacement using the CoreValve system improves aortic valve size and reduces heart failure severity in elderly patients. The procedure has been successfully performed on 17 high-risk patients, with all surviving the operation.
Alain Cribier will describe the development and evolution of percutaneous aortic valve replacement, a breakthrough procedure for treating aortic stenosis. The Cribier-Edwards heart valve has been tested in clinical trials, with another device, CoreValve, also undergoing testing.
The Endeavor III trial reports mixed findings on the new-generation stent, showing improved procedural success but higher late loss in angiographic studies at 8 months compared to the Cypher stent. At 2 years, clinical outcomes were equivalent between the two stents, with similar rates of death, heart attack, and repeat procedures.
The symposium highlights pioneering percutaneous interventions for aortic valve replacement and mitral valve repair, with promising results. Catheter-based stem cell therapy also shows promise in regenerating scarred heart areas and halting enlargement of the heart.